P/E at 34.4 vs Industry's 33.1: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Premium Reflects Sector Confidence

The current P/E of Sun Pharmaceutical Industries Ltd stands at 34.40, slightly above the Pharmaceuticals & Biotechnology industry average of 33.10. This premium, though not excessive, suggests that investors are willing to pay a bit more for the stock relative to its peers. Such a valuation often implies expectations of steady earnings growth or a perception of relative stability within the sector. However, this premium must be weighed against the stock's recent price action and broader sector trends — previously rated Buy, what is Sun Pharma's current rating? The four-parameter analysis factors in the valuation premium.

Performance Across Timeframes: Mixed Signals

Examining the stock's returns reveals a divergence between short- and long-term performance. Over the past year, Sun Pharmaceutical Industries Ltd has gained 6.64%, outperforming the Sensex which declined by 8.40% in the same period. This outperformance extends to the three-year and five-year horizons, with returns of 77.95% and 163.26% respectively, well above the Sensex's 18.24% and 41.58%. However, the 10-year return of 140.88% trails the Sensex's 175.50%, indicating a relative slowdown over the longer term.

In contrast, the recent short-term momentum has been less encouraging. The stock has fallen 3.52% over the last four consecutive trading days, underperforming the sector and the Sensex. The one-week return is -3.62%, worse than the Sensex's -2.52%, and the one-month return is a modest -1.65%, though still better than the Sensex's -3.85%. The three-month return of 1.46% is positive but pales compared to the sector's broader performance. This suggests a recent loss of momentum despite the longer-term strength — is this a temporary setback or a sign of deeper weakness?

Moving Average Configuration: A Mixed Technical Picture

The technical setup for Sun Pharmaceutical Industries Ltd is equally nuanced. The stock currently trades above its 50-day, 100-day, and 200-day moving averages, signalling that the medium- to long-term trend remains intact. However, it is below the 5-day and 20-day moving averages, indicating short-term weakness or consolidation. This configuration often points to a recent pullback within an overall uptrend, suggesting that the stock may be undergoing a pause or minor correction rather than a full reversal. The 4-day consecutive decline and underperformance relative to the sector reinforce this interpretation — is this a genuine recovery or a relief rally that will fade at the 50 DMA? — the moving average configuration provides the clearest answer.

Sector Context: Pharmaceuticals & Biotechnology Showing Resilience

The Pharmaceuticals & Biotechnology sector has seen a mixed bag of results recently. Out of 34 stocks that have declared results, 19 reported positive outcomes, 9 were flat, and 6 posted negative results. This overall positive skew suggests a sector that is largely stable or growing, which supports the valuation premium observed in Sun Pharmaceutical Industries Ltd. The stock's relative outperformance over the past year aligns with this sector strength, though the recent short-term weakness may reflect sector rotation or profit-taking within the space.

Rating Context: Previously Rated Buy, Now Reassessed

Sun Pharmaceutical Industries Ltd was previously rated Buy by MarketsMOJO, with a Mojo Score of 67.0. The rating was updated on 1 June 2026, reflecting the latest data and performance trends. This reassessment takes into account the valuation premium, the mixed short-term momentum, and the technical signals from moving averages. The stock's large-cap status and sector positioning remain important factors in the evaluation — should investors in Sun Pharma hold, buy more, or reconsider?

Conclusion: Data Reflects a Stock in Transition

The data for Sun Pharmaceutical Industries Ltd paints a picture of a stock balancing between valuation premium and recent momentum challenges. Its P/E ratio modestly exceeds the industry average, signalling investor confidence, while its long-term returns have outpaced the Sensex significantly over three and five years. Yet, the recent four-day losing streak and short-term underperformance relative to the sector and Sensex highlight caution. The moving average configuration suggests a pause within a broader uptrend rather than a breakdown, but the short-term weakness cannot be ignored — what is the current rating for Sun Pharmaceutical Industries Ltd?

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →